Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer

Revista Brasileira de Ginecologia e Obstetrícia

Marcos Desídérío Ricci¹  Maria Carolina Formigoni¹  Lucia Maria Martins Zuliani¹  Denis Seiiti Aoki¹  Bruna Salani Mota¹  José Roberto Filassi¹  José Roberto Morales Piato¹  Edmund Chada Baracat¹ 

关键词: Body mass index;    Chemotherapy;    adjuvant;    Breast neoplasms/drug therapy;    Obesity;    Overweight;    Índice de massa corpórea;    Quimioterapia adjuvante;    Neoplasias da mama/quimioterapia;    Obesidade;    Sobrepeso;   

DOI  :  10.1590/S0100-720320140005081

来源: SciELO

【 摘 要 】

PURPOSE:To evaluate variations in the body mass index in patients undergoing adjuvant chemotherapy for breast cancer, and to associate these changes with patient's age and adjuvant chemotherapy regimen.METHODS:We performed a retrospective cohort study in order to correlate any variation in the body mass index before and after adjuvant chemotherapy with patient's age and adjuvant chemotherapy regimen. Patients who received any form of prior hormone therapy, such as tamoxifen or aromatase inhibitors, were excluded. We selected data for 196 patients with stage I to III breast cancer who were treated by radical or conservative surgery and received adjuvant chemotherapy at the Cancer Institute of the State of São Paulo, Brazil.RESULTS:Before adjuvant chemotherapy, 67.8% of patients were classified as overweight or obese according to their body mass indices. Around 66.3% (95% CI 59.7–73.0) of the patients exhibited an increase in the body mass index after adjuvant chemotherapy. The average age of all patients was 56.3±11.3 years. Participants whose body mass index increased were younger than those with no increase (54.7±11.1 versus 59.3±11.2 years; p=0.007). Patients were treated with the following adjuvant chemotherapy regimens: doxorubicin, cyclophosphamide, and paclitaxel (AC-T, 129 patients, 65.8%); 5-fluoracil, doxorubicin, and cyclophosphamide (36 patients, 18.4%); cyclophosphamide, methotrexate, and 5-fluoracil (16 patients, 8.2%); docetaxel and cyclophosphamide (7 patients, 3.6%); and other regimen (8 patients, 4.1%). The AC-T regimen showed a statistically significant association with increase in the body mass index (p<0.001 by ANOVA).CONCLUSIONS:Most patients with breast cancer showed an increase in the body mass index after adjuvant chemotherapy, especially after the AC-T chemotherapy regimen.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License